Enliven Therapeutics Inc. (ELVN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $50.37 (+0.26%), Market cap $2.52B, 52-week low–high $15.14 ~ $48.11.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Financial statements, price targets, institutional (13F) holdings and related news for Enliven Therapeutics Inc. are updated in real time on BlackAll Trade.
Enliven Therapeutics Inc. trades at $50.37 (+0.26%). Real-time quotes and charts are available on BlackAll Trade.
Enliven Therapeutics Inc. has a market cap of about $2.52B.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs compri